Otto A Sanchez1, Daniel A Duprez2, Hossein Bahrami3, Lori B Daniels4, Aaron R Folsom5, Joao A Lima6, Alan Maisel4, Carmen A Peralta7, David R Jacobs8. 1. School of Public Health, Division of Epidemiology & Community Health, University of Minnesota. Electronic address: sanc0050@umn.edu. 2. Division of Cardiology, University of Minnesota. 3. Stanford University. 4. School of Medicine, University of California, San Diego. 5. School of Public Health, Division of Epidemiology & Community Health, University of Minnesota. 6. Division of Cardiology, Johns Hopkins Bayview Medical Center. 7. School of Medicine, University of California San Francisco. 8. School of Public Health, Division of Epidemiology & Community Health, University of Minnesota and University of Oslo.
Abstract
OBJECTIVE: Under physiological conditions brain natriuretic peptide (BNP) is inversely associated with metabolic risk factors, but under pathological conditions these associations may tend to plateau. MATERIAL AND METHODS: 5597 individuals in the Multi-Ethnic Study of Atherosclerosis (MESA), 45-84years of age, free of overt cardiovascular disease in 2000-02 and then again in 2003-05 participated in this study. Associations between NT-proBNP and BMI, blood lipids, homeostasis model of insulin resistance (HOMA-IR) using linear regression models were adjusted for age, race, sex, BMI, % of energy from saturated fats, intentional exercise, statin use, antihypertensive medication use, diabetes and glomerular filtration rate. The inflection points (IP) at which these associations became nonlinear were determined using linear splines with knots at different levels of NT-proBNP. RESULTS: Participants with NT-proBNP ≥100pg/mL (29%) tended to be older, on statins and anti-hypertensive medications vs. those with NT-proBNP <100pg/mL. The IP point varies among variables and ranged from 50-120pg/mL. NT-proBNP<IP, associated inversely with BMI, total cholesterol (TC), LDL-C, triglycerides (TG) and HOMA-IR, but positively with HDL-C. A higher proportion of participants with NT-proBNP ≥100pg/mL had subclinical CVD. All associations with NT-proBNP plateaued when NT-proBNP≥IP. Baseline level in NT-proBNP was not associated with 3-year change in BMI, TG, HDL-C or fasting glucose. CONCLUSIONS: In a large cardiovascular disease-free cohort, NT-proBNP within the lower (physiological) range was inversely associated with TC, LDL-C, TG and insulin resistance with different inflection points, but at higher (pathological) levels these associations were blunted.
OBJECTIVE: Under physiological conditions brain natriuretic peptide (BNP) is inversely associated with metabolic risk factors, but under pathological conditions these associations may tend to plateau. MATERIAL AND METHODS: 5597 individuals in the Multi-Ethnic Study of Atherosclerosis (MESA), 45-84years of age, free of overt cardiovascular disease in 2000-02 and then again in 2003-05 participated in this study. Associations between NT-proBNP and BMI, blood lipids, homeostasis model of insulin resistance (HOMA-IR) using linear regression models were adjusted for age, race, sex, BMI, % of energy from saturated fats, intentional exercise, statin use, antihypertensive medication use, diabetes and glomerular filtration rate. The inflection points (IP) at which these associations became nonlinear were determined using linear splines with knots at different levels of NT-proBNP. RESULTS: Participants with NT-proBNP ≥100pg/mL (29%) tended to be older, on statins and anti-hypertensive medications vs. those with NT-proBNP <100pg/mL. The IP point varies among variables and ranged from 50-120pg/mL. NT-proBNP<IP, associated inversely with BMI, total cholesterol (TC), LDL-C, triglycerides (TG) and HOMA-IR, but positively with HDL-C. A higher proportion of participants with NT-proBNP ≥100pg/mL had subclinical CVD. All associations with NT-proBNP plateaued when NT-proBNP≥IP. Baseline level in NT-proBNP was not associated with 3-year change in BMI, TG, HDL-C or fasting glucose. CONCLUSIONS: In a large cardiovascular disease-free cohort, NT-proBNP within the lower (physiological) range was inversely associated with TC, LDL-C, TG and insulin resistance with different inflection points, but at higher (pathological) levels these associations were blunted.
Authors: P Dessì-Fulgheri; R Sarzani; P Tamburrini; A Moraca; E Espinosa; G Cola; L Giantomassi; A Rappelli Journal: J Hypertens Date: 1997-12 Impact factor: 4.844
Authors: Michael G Fradley; Martin G Larson; Susan Cheng; Elizabeth McCabe; Erin Coglianese; Ravi V Shah; Daniel Levy; Ramachandran S Vasan; Thomas J Wang Journal: Am J Cardiol Date: 2011-08-23 Impact factor: 2.778
Authors: Verônica R S Fernandes; Joseph F Polak; Thor Edvardsen; Benilton Carvalho; Antoinette Gomes; David A Bluemke; Khurram Nasir; Daniel H O'Leary; João A C Lima Journal: J Am Coll Cardiol Date: 2006-05-30 Impact factor: 24.094
Authors: Camilla L Asferg; Søren J Nielsen; Ulrik B Andersen; Allan Linneberg; Daniel V Møller; Paula L Hedley; Michael Christiansen; Jens P Goetze; Murray Esler; Jørgen L Jeppesen Journal: Hypertension Date: 2013-05-13 Impact factor: 10.190
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: Otto A Sanchez; David R Jacobs; Hossein Bahrami; Carmen A Peralta; Lori B Daniels; João A Lima; Alan Maisel; Daniel A Duprez Journal: J Hypertens Date: 2015-05 Impact factor: 4.844
Authors: Otto A Sanchez; Daniel A Duprez; Lori B Daniels; Alan S Maisel; James D Otvos; Carmen A Peralta; João A Lima; Hossein Bahrami; David R Jacobs Journal: Metabolism Date: 2015-04-15 Impact factor: 8.694
Authors: O A Sanchez; D A Duprez; H Bahrami; C A Peralta; L B Daniels; J A Lima; A Maisel; A R Folsom; D R Jacobs Journal: Diabetes Metab Date: 2015-06-03 Impact factor: 6.041
Authors: Wendy Ying; Di Zhao; Pamela Ouyang; Vinita Subramanya; Dhananjay Vaidya; Chiadi E Ndumele; Kavita Sharma; Sanjiv J Shah; Susan R Heckbert; Joao A Lima; Christopher R deFilippi; Matthew J Budoff; Wendy S Post; Erin D Michos Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958
Authors: Sahera Dirajlal-Fargo; Bruce Kinley; Ying Jiang; Chris T Longenecker; Corrilynn O Hileman; Sara Debanne; Grace A McComsey Journal: AIDS Date: 2015-01-28 Impact factor: 4.177
Authors: Otto A Sanchez; Mariana Lazo-Elizondo; Irfan Zeb; Russell P Tracy; Ryan Bradley; Daniel A Duprez; Hossein Bahrami; Carmen A Peralta; Lori B Daniels; João A Lima; Alan Maisel; David R Jacobs; Mathew J Budoff Journal: Metabolism Date: 2016-02-27 Impact factor: 8.694
Authors: Nirav Patel; Orlando M Gutiérrez; Garima Arora; George Howard; Virginia J Howard; Suzanne E Judd; Sumanth D Prabhu; Emily B Levitan; Mary Cushman; Pankaj Arora Journal: Int J Cardiol Date: 2019-02-21 Impact factor: 4.164
Authors: Erika F Brutsaert; Mary L Biggs; Joseph A Delaney; Luc Djoussé; John S Gottdiener; Joachim H Ix; Francis Kim; Kenneth J Mukamal; David S Siscovick; Russell P Tracy; Ian H de Boer; Christopher R deFilippi; Jorge R Kizer Journal: Metabolism Date: 2016-06-24 Impact factor: 8.694
Authors: Wilson Nadruz; Alexandra Gonçalves; Brian Claggett; Gabriela Querejeta Roca; Amil M Shah; Susan Cheng; Gerardo Heiss; Christie M Ballantyne; Scott D Solomon Journal: Eur J Heart Fail Date: 2016-03-30 Impact factor: 15.534